Magnus Vrethem

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman et al. · JAMA Neurology · 2019 · 509 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +10

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Martin Gunnarsson, Clas Malmeström, Markus Axelsson et al. · Annals of Neurology · 2010 · 347 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

Joachim Burman, Ellen Iacobaeus, Anders Svenningsson et al. · Journal of Neurology Neurosurgery & Psychiatry · 2014 · 166 citations

Medicine, Hematology, Neurology +14

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

Johan Mellergård, Måns Edström, Magnus Vrethem et al. · Multiple Sclerosis Journal · 2009 · 151 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

A Comparison of Amitriptyline and Maprotiline in the Treatment of Painful Polyneuropathy in Diabetics and Nondiabetics

Magnus Vrethem, Jörgen Boivie, Hans J. Arnqvist et al. · Clinical Journal of Pain · 1997 · 137 citations

Medicine, Pharmacology, Pharmacotherapy +17